PLX Financial Facts
COST OF REVENUES: -4.25MRESEARCH AND DEVELOPMENT EXPENSES: -6.35M
See Full Income Statement
Total liabilities net of capital deficiency: 70.47M
CAPITAL DEFICIENCY: -15.1M
See Full Balance Sheet
Protalix Biotherapeutics, Inc. (PLX) Earnings
|
Expand Research on PLX
| Next EPS Date | 11/16/26 | EPS Growth Rate | -133.3% |
|---|---|---|---|
| Average EPS % Beat Rate | -2.5% | Revenue Growth Rate | -15.8% |
| Average % Move 1-Wk after EPS | -15.6% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
11/16/26  |
Q326 | N/A | -$0.01 | N/A | N/A | $14.87M | = | N/A | N/A | ||
| 8/17/26 |
Q226 | N/A | $0.12 | N/A | N/A | $12.93M | = | N/A | N/A | ||
| 5/13/26 | Q126 | $0.22 | $0.04 | +$0.18 | $33.75M | $18.7M | = |  | | Details | |
| 3/18/26 | Q425 | -$0.08 | N/A | N/A | $52.74M | $18.35M | = | | | Details | |
| 3/12/26 |
Q425 | N/A | $0.04 | N/A | N/A | $18.35M | N/A | N/A | N/A | ||
| 11/13/25 | Q325 | $0.03 | $0.07 | -$0.04 | $17.67M | $17.79M | N/A | | | Details | |
| 8/14/25 | Q225 | -$0.04 | $0.11 | -$0.15 | $25.77M | $23.1M | N/A | | | Details | |
| 5/9/25 | Q125 | -$0.05 | $0.03 | -$0.08 | $10.11M | $21.6M | N/A | | | Details |
